[Antibes, 5th May 2023] - The prestigious RDD 2023 (Respiratory Drug Delivery) Conference came to a successful conclusion, bringing together key players in the inhalation industry from around the world. This internationally renowned event provided an opportunity to discuss the latest technological advances, innovative research and collaborative opportunities to shape the future of respiratory therapy.
Among the conference's prominent participants, leading companies in the field of inhalation therapies, played a central role in sharing their expertise and recent developments. As a pioneer in the design and commercialization of advanced inhalation products, Inhaled Therapeutics confirmed its role to play to bring innovative treatments and unveiled major innovations that will shape the future of respiratory therapy.
Inhaled Therapeutics' scientific director, Pascal Cavaillon, participated to captivating keynotes highlighting the ongoing commitment to the research and development of cutting-edge inhaled therapies. It stressed the importance of collaboration between industry players and academic institutions to accelerate the development of breakthrough treatments.
In conjunction with the conference, our team actively participated in workshops, roundtables and bilateral meetings with other industry thought leaders. These exchanges helped establish new strategic collaborations and strengthen existing partnerships, with the aim of better meeting the needs of patients suffering from respiratory diseases.
About the RDD Conference:
The RDD Conference is the must-attend event for experts in the field of inhalation. Held annually, it offers a unique platform for sharing scientific knowledge, exchanging best practices and discovering emerging technologies in the field of respiratory therapies.
About Inhaled Therapeutics:
Inhaled Therapeutics is a pharmaceutical company dedicated to make new inhaled drug technically and economically affordable. Founded on innovation and scientific excellence, the company develops advanced inhalation solutions to optimize drug delivery and maximize efficacy for better care around respiratory therapies and beyond.
For more information about Inhaled Therapeutics and its advances in inhalation therapies, please contact:
Raphaël WITTMER – Project Manager
rwittmer@isalys.eu
コメント